Recently, many state-of-the-art omics technologies are being applied to systems toxicology research because evaluation of toxicity in pre-clinical trials is a big issue in the pharmaceutical industry. Now, genetic polymorphisms are also considered in systems toxicology because polymorphism information can be used to explain individual-specific toxicity and/or side effects. However, in spite of its importance, no well-organized database for individual toxicity has been reported to date. To address this issue, we first extracted toxicity-related human gene information from the CTD, and then, using comparative genomics techniques and retrieving information from animal databases, we gathered the corresponding genes from the mouse and rat. The CTD (Comparative Toxicogenomics Database), dbSNP, RGD (Rat Genome Database), MGI (Mouse Genome Informatics), NHGRI Genome-Wide Association Studies, JMDBASE (Japan Metabolic Disease Database) and GAD (Genetic Association Database) were used as original information sources. The dbSNP was used as a major polymorphism data source, and other related databases were also used to find disease- and/or toxicity-related SNPs. The MSSQL server was used as a database management system and ASP was used to construct a database-web interface. The result of our efforts is TOXPO(TOXico-genomics knowledgebase for inferring toxicity based on POlymorphism), the first database managing toxicogenomics information based on genomic variation. This database is freely available on website http://188.8.131.52/toxpo.
Toxicogenomics SNP Bioinformatics Systems toxicology Database
This is a preview of subscription content, log in to check access.
Schwardt, O., Kolb, H. & Ernst, B. Drug discovery today. Current Topics in Medicinal Chemistry3, 1–9 (2003).CrossRefGoogle Scholar
Yang, Y., Blomme, E.A.G. & Waring, J.F. Toxicogenomics in drug discovery: from preclinical studies to clinical trials. Chemico-Biological Interactions150, 71–85 (2004).CrossRefGoogle Scholar
Nuwaysir, E.F., Bittner, M., Trent, J., Barrett, J.C. & Afshari, A. Microarrays and toxicology: The advent of toxicogenomics. Molecular Carcinogenesis24, 153–159 (1999).CrossRefGoogle Scholar
Giacomini, K.M. et al. The pharmacogenetics research network: From SNP discovery to clinical drug response. Clinical Pharmacology & Therapeutics81, 328–345 (2007).CrossRefGoogle Scholar
Voisey, J. & Morris, C.P. SNP Technologies for drug discovery: A current review. Current Drug Discovery Technologies5, 230–235 (2008).CrossRefGoogle Scholar
Glubb, D.M., McHugh, P.C., Deng, X., Joyce, P.R. & Kennedy, M.A. Association of a functional polymorphism in the adrenomedullin gene (ADM) with response to paroxetine. The Pharmacogenomics Journal10, 126–133 (2010).CrossRefGoogle Scholar
Wandel, C. et al. CYP3A activity in African American and European American men: Population differences and functional effect of the CYP3A4*1B 5′-promoter region polymorphism. Clinical Pharmacology & Therapeutics68, 82–91 (2000).CrossRefGoogle Scholar
The International HapMap Consortium. A second generation human haplotype map of over 3.1 million SNPs. Nature449, 851–861 (2007).CrossRefGoogle Scholar
Grapes, L. et al. Prospecting for pig single nucleotide polymorphisms in the human genome: have we struck gold? J. Anim. Breed. Genet.123, 145–151 (2006).CrossRefGoogle Scholar
Ng, P.C., Murray, S.S., Levy, S. & Venter, J.C. An agenda for personalized medicine. Nature461, 724–726 (2009).CrossRefGoogle Scholar
Kong, A. et al. Parental origin of sequence variants associated with complex diseases. Nature462, 868–874 (2009).CrossRefGoogle Scholar
Cooper, D.N., Nussbaum, R.L. & Krawczak, M. Proposed guidelines for papers describing DNA polymorphism-disease associations. Hum. Genet.110, 207–208 (2002).CrossRefGoogle Scholar
Nan, H., Kraft, P., Hunter, D.J. & Han, J. Genetic variants in pigmentation genes, pigmentary phenotypes, and risk of skin cancer in Caucasians. Int. J. Cancer125, 909–917 (2009).CrossRefGoogle Scholar